



Supplementary Fig. 1. Percentage of migrating cells in differentiated-stimulated HL-60 after transfection with siMEFV and negative control and non-transfected cells in fMLP negative and fMLP positive conditions.

Error bars indicate standard deviations. Statistically significant differences are indicated as $*p < 0.05$. NT: non-transfected control Experiments were performed biologically and technically in triplicate.



Supplementary Fig. 2. Western Blot analysis for pyrin (Uncropped - unadjusted blots of siRNA transfection). The pyrin protein level is decreased compared with that in the negative control and control cells. Two bands indicated two isoforms of the MEFV gene that were translated in HL-60 cells. NT: non-transfected control. Experiments were performed biologically and technically in triplicate.




Supplementary Fig. 3. Unstimulated neutrophil polarization in FMF patients and healthy individuals. The polarization rate did not change in unstimulated neutrophils isolated from M694V homozygote patients. Error bars indicate standard deviations. Experiments were performed technically in duplicate.

Supplementary Table 1. Erythrocyte sedimentation rate (ESR), level of C reactive protein (CRP) and attack frequency/disease state of FMF patients with different types of mutations and healthy individuals.

Individuals involved	AGE (0 – 20 mm/h)	ESR (0 -0.8 mg/dL)	CRP	Mutation	Attack frequency ^a /disease state in the study
Patient 1	7	11	0,726	M694V/M680I	4 attacks/Attack-free period
Patient 2	10	59	2,5	M694V/M680I	0 attack/Attack-free period
Patient 3	17	5	0,238	M694V/M680I	2 attacks/Attack-free period
Patient 4	8	15	0,371	M694V/M680I	4 attacks/Attack-free period
Patient 5	12	12	0,169	M694V/M680I	0 attack/Attack-free period
Patient 6	9	23	1,31	M694V/M680I	1 attack/Attack-free period
Patient 7	12	7	0,334	M694V/V726A	0 attack/Attack-free period
Patient 8	7	2	0,267	M694V/V726A	1 attack/Attack-free period
Patient 9	10	5	0,202	M694V/V726A	0 attack/Attack-free period
Patient 10	13	2	0,129	M694V/E148Q	0 attack/Attack-free period
Patient 11	7	21	0,279	M694V/E148Q	4 attacks/Attack-free period
Patient 12	4	2	0,103	M694V/E148Q	2 attacks/Attack-free period
Patient 13	7	3	0,147	E148Q/E148Q	3 attacks/Attack-free period
Patient 14	11	20	0,813	E148Q/E148Q	0 attack/Attack-free period
Patient 15	14	4	0,116	E148Q/E148Q	0 attack/Attack-free period
Control 1	16	2	0,215	-	Healthy
Control 2	16	7	0,106	-	Healthy
Control 3	12	2	0,262	-	Healthy
Control 4	6	2	0,101	-	Healthy
Control 5	6	6	0,169	-	Healthy
Control 6	4	2	0,216	-	Healthy
Control 7	14	2	0,106	-	Healthy
Control 8	9	9	0,215	-	Healthy
Control 9	13	2	0,216	-	Healthy

^aNumber of attacks during the previous year.



Supplementary Fig. 4. Comparison of the stimulated cell migration ratio in FMF patients with the compound heterozygous genotype with FMF patients homozygous for the E148Q mutation. (A) The number of migrated cells was increased significantly in M694V/M680I patients. (B) The number of migrated cells was higher in M694V/V726A patients. (C) The number of migrated cells was higher in M694V/E148Q patients than in E148Q/E148Q patients. Error bars indicate standard deviations. Statistically significant differences are indicated as * $p < 0.05$. Experiments were performed technically in duplicate.

Supplementary Fig. 5. Comparison of the stimulated cell migration ratio in FMF patients with the compound heterozygous genotype. (A) The number of migrated cells was increased in M694V/V726A patients. (B) The number of migrated cells was higher in M694V/M680I patients than in M694V/E148Q patients. Error bars indicate standard deviations. Experiments were performed technically in duplicate.